Core Insights - The company reported a revenue of 2.544 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 13.50%, and a net profit attributable to shareholders of 362 million yuan, up 45.64% year-on-year [1] - In Q3 2025, the company achieved a revenue of 837 million yuan, with a year-on-year increase of 1.44%, and a net profit of 106 million yuan, reflecting a growth of 23.02% year-on-year [1] - The company has made significant advancements in mRNA vaccine development, including obtaining the world's first clinical trial approval for a food animal mRNA vaccine, showcasing its technological strength and forward-looking capabilities in the veterinary vaccine sector [1] Product Development - In Q3, the company received approvals for seven new products across various categories, including biological products, chemical drugs, and antibodies, enhancing its product matrix in the pet and animal medicine sectors [2] - The new products include vaccines for Newcastle disease, infectious bronchitis, avian adenovirus, and several others, which will drive high-quality development for the company [2] - The company has also adjusted the use of some raised funds to support the construction of a biological manufacturing industrialization project, aiming to expand into the new high-quality alternative protein sector [2] Operational Efficiency - The company has improved its profitability model through cost reduction and value innovation, leading to enhanced production efficiency and reduced operational costs [3] - During the reporting period, the sales and management expense ratios decreased by 0.27 percentage points year-on-year [3] - Looking ahead, the company is expected to maintain a competitive edge in the animal health sector and explore new growth opportunities through continued investment in mRNA vaccines and the development of ruminant vaccines [3]

人民财讯8月14日电，瑞普生物（300119）8月14日晚间公告，公司及全资子公司瑞普(天津)生物药业有 限公司、瑞普(保定)生物药业有限公司近日获得由农业农村部核发的《新兽药注册证书》，新兽药名称 分别为禽腺病毒(I群，4型)蛋黄抗体、青霉素V钾可溶性粉。 ...

Core Viewpoint - The company, Reap Bio (300119.SZ), has recently received two new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs, indicating a significant advancement in its product offerings in the animal health sector [1] Group 1: Product Details - The first product is an avian adenovirus (Group I, Type 4) yolk antibody, which is primarily used for the prevention and treatment of chicken pericardial effusion-hepatitis syndrome caused by Group I Type 4 avian adenovirus. It has the ability to neutralize the virus, alleviate hepatocyte necrosis and pericardial effusion, and promote the recovery of organ function [1] - The second product is soluble penicillin V potassium powder, which is mainly used to treat necrotic enteritis in chickens caused by Clostridium perfringens. It features a one-day withdrawal period and a zero-day egg discard period, providing core advantages in reducing drug residue risks and ensuring chicken meat food safety [1]